Market revenue in 2023 | USD 1,100.7 million |
Market revenue in 2030 | USD 1,763.6 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer’s disease dementia |
Fastest growing segment | Lewy Body Dementia |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia, Other Indications |
Key market players worldwide | Eisai Co Ltd, Eli Lilly and Co, Novartis AG ADR, Daiichi Sankyo Co Ltd, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Cipla Ltd DR, Sun Pharmaceutical Industries, Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dementia treatment market will help companies and investors design strategic landscapes.
Alzheimer’s disease dementia was the largest segment with a revenue share of 60.22% in 2023. Horizon Databook has segmented the Germany dementia treatment market based on alzheimer’s disease dementia, vascular dementia, lewy body dementia, frontotemporal dementia (ftd), parkinson disease dementia, other indications covering the revenue growth of each sub-segment from 2018 to 2030.
The dementia treatment market in Germany is expected to grow rapidly in the forecast period. Germany has made significant progress in addressing dementia, with research and funding playing a crucial role. For instance, In September 2023, a study by the Robert Koch Institute in Germany predicted a rise in dementia cases from 1.7 million in 2023 to 3.0 million cases by 2070 in Germany.
The German Federal Ministry of Education and Research has been at the forefront of dementia research, while the EU Joint Programme – Neurodegenerative Disease Research (JPND) has launched a transnational call for health and social care research.
Notably, Germany contributed to global efforts, aiming to find a treatment for Alzheimer’s by 2025. This commitment is demonstrated by conferences such as ISAD-2025 in Berlin, which highlights the nation’s focus on dementia treatment.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany dementia treatment market, including forecasts for subscribers. This country databook contains high-level insights into Germany dementia treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account